Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced the annual results for the year ended 31 December … More
Tag: Essex Bio -Technology Limited
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited … More
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases
Essex Bio-Technology Ltd (Essex or the Group, HKG: 1061) today announced that the first patient in the United States (US) … More
Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech
Essex Bio-Technology Limited (the Company, together with its subsidiaries, the Group) wishes to announce that Essex Bio-Investment Limited (Essex Bio-Investment), … More
Essex Bio-Technology Announces 2021 Financial Results
Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million Essex Bio-Technology … More
SciTech World News 